Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and lapatinib.Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.